FDA Approves Ivosidenib Tablets for IDH1-Mutated Cholangiocarcinoma

Ivosidenib tablets have been granted FDA approval for the treatment of adult patients with cholangiocarcinoma, a rare and aggressive cancer affecting the bile ducts both in and outside of the liver. “Patients living with IDH1-mutated cholangiocarcinoma, especially those whose disease progresses following chemotherapy, are in urgent need of new treatment options,” Rachna T. Shroff, MD, associate professor of medicine at the College of Medicine – Tucson and chief of GI medical oncology at the UArizona Cancer Center.